Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.19
CRL's Cash to Debt is ranked higher than
51% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. CRL: 0.19 )
CRL' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 0.19

Equity to Asset 0.36
CRL's Equity to Asset is ranked higher than
57% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. CRL: 0.36 )
CRL' s 10-Year Equity to Asset Range
Min: -0.28   Max: 0.72
Current: 0.36

-0.28
0.72
Interest Coverage 7.22
CRL's Interest Coverage is ranked higher than
53% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. CRL: 7.22 )
CRL' s 10-Year Interest Coverage Range
Min: 1.6   Max: 83.91
Current: 7.22

1.6
83.91
F-Score: 7
Z-Score: 2.60
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.85
CRL's Operating margin (%) is ranked higher than
89% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. CRL: 12.85 )
CRL' s 10-Year Operating margin (%) Range
Min: -33.48   Max: 22.58
Current: 12.85

-33.48
22.58
Net-margin (%) 9.44
CRL's Net-margin (%) is ranked higher than
90% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. CRL: 9.44 )
CRL' s 10-Year Net-margin (%) Range
Min: -38.84   Max: 14.3
Current: 9.44

-38.84
14.3
ROE (%) 17.71
CRL's ROE (%) is ranked higher than
93% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. CRL: 17.71 )
CRL' s 10-Year ROE (%) Range
Min: -230.9   Max: 58.93
Current: 17.71

-230.9
58.93
ROA (%) 6.86
CRL's ROA (%) is ranked higher than
87% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. CRL: 6.86 )
CRL' s 10-Year ROA (%) Range
Min: -21.02   Max: 10.68
Current: 6.86

-21.02
10.68
ROC (Joel Greenblatt) (%) 18.48
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. CRL: 18.48 )
CRL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.63   Max: 83.75
Current: 18.48

-50.63
83.75
Revenue Growth (3Y)(%) 9.90
CRL's Revenue Growth (3Y)(%) is ranked higher than
82% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. CRL: 9.90 )
CRL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.6   Max: 13.4
Current: 9.9

-17.6
13.4
» CRL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CRL Guru Trades in Q4 2013

Steven Cohen 38,698 sh (+67.7%)
Pioneer Investments 131,209 sh (+29.64%)
David Dreman 212,072 sh (+12.88%)
Paul Tudor Jones 9,300 sh (+6.9%)
Ken Fisher 54,280 sh (+3.59%)
PRIMECAP Management 1,697,800 sh (unchged)
Westport Asset Management 155,000 sh (unchged)
RS Investment Management 689,250 sh (-1.08%)
Robert Olstein 169,000 sh (-3.98%)
John Rogers 2,629,217 sh (-4.39%)
Jim Simons 666,709 sh (-26.43%)
Joel Greenblatt 21,759 sh (-47.51%)
» More
Q1 2014

CRL Guru Trades in Q1 2014

Ken Fisher 210,712 sh (+288.19%)
Paul Tudor Jones 16,761 sh (+80.23%)
Pioneer Investments 163,867 sh (+24.89%)
Jim Simons 801,418 sh (+20.21%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,697,800 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
RS Investment Management 647,325 sh (-6.08%)
John Rogers 2,009,262 sh (-23.58%)
David Dreman 152,159 sh (-28.25%)
Robert Olstein 81,000 sh (-52.07%)
» More
Q2 2014

CRL Guru Trades in Q2 2014

Joel Greenblatt 11,280 sh (New)
Ken Fisher 371,824 sh (+76.46%)
Robert Olstein 133,000 sh (+64.2%)
Paul Tudor Jones 18,094 sh (+7.95%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,696,800 sh (-0.06%)
John Rogers 1,950,657 sh (-2.92%)
RS Investment Management 615,915 sh (-4.85%)
Pioneer Investments 123,177 sh (-24.83%)
David Dreman 109,870 sh (-27.79%)
Jim Simons 333,109 sh (-58.44%)
» More
Q3 2014

CRL Guru Trades in Q3 2014

Steven Cohen 131,400 sh (New)
Ray Dalio 4,200 sh (New)
Pioneer Investments 221,616 sh (+79.92%)
Jim Simons 358,809 sh (+7.72%)
John Rogers 1,996,270 sh (+2.34%)
David Dreman 111,247 sh (+1.25%)
Westport Asset Management 155,000 sh (unchged)
Joel Greenblatt Sold Out
PRIMECAP Management 1,692,800 sh (-0.24%)
Ken Fisher 368,208 sh (-0.97%)
RS Investment Management 585,890 sh (-4.87%)
Robert Olstein 121,000 sh (-9.02%)
Paul Tudor Jones 11,800 sh (-34.79%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$52.24 - $61.2 $ 63.5911%0
Ray Dalio 2014-09-30 New Buy$52.24 - $61.2 $ 63.5911%4200
Robert Olstein 2014-06-30 Add 64.2%0.38%$50.74 - $61.47 $ 63.5916%133000
David Dreman 2014-06-30 Reduce -27.79%0.2%$50.74 - $61.47 $ 63.5916%109870
Ken Fisher 2014-06-30 Add 76.46%0.02%$50.74 - $61.47 $ 63.5916%371824
Joel Greenblatt 2014-06-30 New Buy0.01%$50.74 - $61.47 $ 63.5916%11280
Robert Olstein 2014-03-31 Reduce -52.07%0.68%$52.88 - $62.01 $ 63.5910%81000
John Rogers 2014-03-31 Reduce -23.58%0.4%$52.88 - $62.01 $ 63.5910%2009262
David Dreman 2014-03-31 Reduce -28.25%0.24%$52.88 - $62.01 $ 63.5910%152159
Joel Greenblatt 2014-03-31 Sold Out 0.03%$52.88 - $62.01 $ 63.5910%0
Ken Fisher 2014-03-31 Add 288.19%0.02%$52.88 - $62.01 $ 63.5910%210712
Joel Greenblatt 2013-12-31 Reduce -47.51%0.03%$44.67 - $53.36 $ 63.5927%21759
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc - Jul 22, 2014

Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately.

From John Rogers (Trades, Portfolio)' Ariel Fund Second Quarter 2014 Commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc
Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately. Read more...
John Rogers' Ariel Fund Second Quarter 2014 Commentary
Quarter Ended June 30, 2014 Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
CRL's P/E(ttm) is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 25.60 )
CRL' s 10-Year P/E(ttm) Range
Min: 8.59   Max: 95.93
Current: 25.6

8.59
95.93
P/B 4.40
CRL's P/B is ranked higher than
71% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. CRL: 4.40 )
CRL' s 10-Year P/B Range
Min: 0.75   Max: 5.58
Current: 4.4

0.75
5.58
P/S 2.40
CRL's P/S is ranked higher than
77% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. CRL: 2.40 )
CRL' s 10-Year P/S Range
Min: 1.12   Max: 3.91
Current: 2.4

1.12
3.91
PFCF 17.70
CRL's PFCF is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 17.70 )
CRL' s 10-Year PFCF Range
Min: 8.48   Max: 907.57
Current: 17.7

8.48
907.57
EV-to-EBIT 22.47
CRL's EV-to-EBIT is ranked higher than
85% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 22.47 )
CRL' s 10-Year EV-to-EBIT Range
Min: -10.7   Max: 72.4
Current: 22.47

-10.7
72.4
Current Ratio 2.14
CRL's Current Ratio is ranked higher than
66% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. CRL: 2.14 )
CRL' s 10-Year Current Ratio Range
Min: 1.21   Max: 3.49
Current: 2.14

1.21
3.49
Quick Ratio 1.81
CRL's Quick Ratio is ranked higher than
65% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. CRL: 1.81 )
CRL' s 10-Year Quick Ratio Range
Min: 0.95   Max: 3.02
Current: 1.81

0.95
3.02

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.95
CRL's Price/Tangible Book is ranked higher than
66% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. CRL: 13.95 )
CRL' s 10-Year Price/Tangible Book Range
Min: 2.86   Max: 40.21
Current: 13.95

2.86
40.21
Price/DCF (Projected) 1.36
CRL's Price/DCF (Projected) is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 1.36 )
CRL' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 1.78
Current: 1.36

0.94
1.78
Price/Median PS Value 1.07
CRL's Price/Median PS Value is ranked higher than
80% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. CRL: 1.07 )
CRL' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 1.84
Current: 1.07

0.55
1.84
Price/Graham Number 3.91
CRL's Price/Graham Number is ranked higher than
85% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 3.91 )
CRL' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 8.23
Current: 3.91

1.66
8.23
Earnings Yield (Greenblatt) 4.50
CRL's Earnings Yield (Greenblatt) is ranked higher than
85% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. CRL: 4.50 )
CRL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 13.7
Current: 4.5

1.4
13.7
Forward Rate of Return (Yacktman) 9.07
CRL's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. CRL: 9.07 )
CRL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.8   Max: 22
Current: 9.07

2.8
22

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RV6.Germany,
Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000 it completed its initial public offering. Its portfolio includes research models and services required to enablein vivo drug discovery and development. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candidate is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in two segments, namely Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company supplies research models to the drug development industry. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. With multiple facilities located on three continents (North America, Europe and Asia), it maintains production centers, including barrier rooms and/or isolator facilities. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. Its RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection. Its Research Models business is comprised of the production and sale of research models and avian vaccine services. Research Model Services also offers a variety of services designed to support its clients' use of research models in screening drug candidates. Its Endotoxin and Microbial Detection business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. The Company currently offers preclinical services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Company's customers include global biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace on the basis of therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The Company's business operates in a num
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 
Ken Heebner Top Holdings: AAPL Is a Buy at $380 Jan 11 2012 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Aug 03 2010 


More From Other Websites
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Amendments to Articles of Inc. or... Dec 02 2014
How Much to End a Marriage? Almost $1 Billion For Harold Hamm Nov 10 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials Nov 06 2014
Strength Seen in Covance (CVD): Stock Surges 25.9% Nov 04 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal... Nov 03 2014
10-Q for Charles River Laboratories International, Inc. Nov 01 2014
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong Oct 30 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 30 2014
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped Oct 30 2014
Charles River Laboratories International Inc Earnings Call scheduled for 9:00 am ET today Oct 30 2014
Charles River beats Street 3Q forecasts Oct 29 2014
Charles River beats Street 3Q forecasts Oct 29 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Oct 29 2014
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations Oct 29 2014
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations Oct 29 2014
Express Scripts Reports In-Line Q3 Earnings, Narrows View Oct 29 2014
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance Oct 29 2014
Q3 2014 Charles River Laboratories International Inc Earnings Release - After Market Close Oct 29 2014
Why Earnings Season Could Be Great for Charles River Laboratories International (CRL) Oct 28 2014
Omnicare Beats on Q3 Earnings and Sales, Outlook Positive Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK